Authors and Reference | Primary disease | Treatment approach | Dose | Response |
---|---|---|---|---|
Gaya et al. [8] | Orofacial granulomatosis | Infliximab followed by adalimumab | 5 mg/kg | Responded initially, lost to follow-up, partial response later |
Barry et al. [9] | Granulomatous cheilitis | Infliximab | 3 mg/kg initially followed by 5 mg/kg | Initial relapse at 3 mg/kg but sustained response at 5 mg/kg |
Kakimoto et al. [11] | Melkersson–Rosenthal Syndrome | Infliximab followed by adalimumab | 5 mg/kg | Adverse reaction to infliximab but sustained response to adalimumab |
Ruiz Villaverde and Sánchez Cano [12] | Granulomatous cheilitis | Adalimumab | 80 mg followed by 40 mg | Sustained response post 6 month treatment |
Stein et al. [13] | Melkersson–Rosenthal Syndrome | Adalimumab | 80 mg followed by 40 mg | Sustained response post 21 month treatment |
Peitsch et al. [14] | Orofacial granulomatosis | Infliximab | 5 mg/kg | Sustained response |